Clinical trial
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active…
NCT00329446 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00329446 |
|---|---|
| Title | Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder |
| Acronym | GOLD |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Anxiety Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate, Escitalopram oxylate |
| Enrollment | 800 |
| Start date | Apr 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | May 24, 2006 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: